A phase II study of GW786034 (Pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer

Clinical Genitourinary Cancer

Volumn 13, Issue 2, 2015, Pages 124-129

  Sridhar, Srikala S ^a   Joshua, Anthony M ^a   Gregg, Richard ^b   Booth, Christopher M ^b   Murray, Nevin ^c   Golubovic, Jovana ^a   Wang, Lisa ^a   Harris, Pamela ^d   Chi, Kim N ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis inhibitors; CRPC; Patient selection; PSA response

Indexed keywords

ABIRATERONE; ALANINE AMINOTRANSFERASE; BICALUTAMIDE; ENZALUTAMIDE; PAZOPANIB; PROSTATE SPECIFIC ANTIGEN; ANGIOGENESIS INHIBITOR; ANILIDE; ANTINEOPLASTIC AGENT; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; NITRILE; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TOLUENESULFONIC ACID DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; HUMAN; HYPERTENSION; MALE; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANILIDES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PYRIMIDINES; SULFONAMIDES; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84924558148     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.06.001     Document Type: Article

References (40)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. O. Kucuk, E. Fisher, and C.M. Moinpour Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235) Urology 58 2001 53 58
3. R. Joyce, M.A. Fenton, and P. Rode High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy J Urol 159 1998 149 153
4. H.I. Scher, C. Liebertz, and W.K. Kelly Bicalutamide for advanced prostate cancer: the natural versus treated history of disease J Clin Oncol 15 1997 2928 2938
5. F.A. Ferrer, L.J. Miller, and R. Lindquist Expression of vascular endothelial growth factor receptors in human prostate cancer Urology 54 1999 567 572
6. N. Weidner, P.R. Carroll, J. Flax, W. Blumenfeld, and J. Folkman Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am J Pathol 143 1993 401 409
7. I.F. Lissbrant, P. Stattin, J.E. Damber, and A. Bergh Vascular density is a predictor of cancer-specific survival in prostatic carcinoma Prostate 33 1997 38 45
8. M.A. Silberman, A.W. Partin, R.W. Veltri, and J.I. Epstein Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate Cancer 79 1997 772 779
9. J.L. Duque, K.R. Loughlin, R.M. Adam, P.W. Kantoff, D. Zurakowski, and M.R. Freeman Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer Urology 54 1999 523 527
10. D.J. George, S. Halabi, and T.F. Shepard Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480 Clin Cancer Res 7 2001 1932 1936
11. R.A. Bok, S. Halabi, and D.T. Fei Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a Cancer and Leukemia Group B study Cancer Res 61 2001 2533 2536
12. M.T. Schweizer, and M.A. Carducci From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer Cancer J 19 2013 99 106
13. B. Nicholson, and D. Theodorescu Angiogenesis and prostate cancer tumor growth J Cell Biochem 91 2004 125 150
14. I.B. Joseph, J.B. Nelson, S.R. Denmeade, and J.T. Isaacs Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue Clin Cancer Res 3 1997 2507 2511
15. A. Meyer, P. Cygan, and K. Tolzien Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer Clin Genitourin Cancer 2013
16. W.K. Kelly, S. Halabi, and M. Carducci Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401 J Clin Oncol 30 2012 1534 1540
17. E.K. Beardsley, S.J. Hotte, and S. North A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer Invest New Drugs 30 2012 1652 1659
18. P.G. Corn, D.Y. Song, and E. Heath Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study Int J Radiat Oncol Biol Phys 86 2013 540 545
19. A.J. Zurita, D.J. George, and N.D. Shore Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial Ann Oncol 23 2012 688 694
20. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New Response Evaluation Criteria in Solid Tumors: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
21. G.J. Bubley, M. Carducci, and W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467
22. D.C. Smith, R.L. Dunn, M.S. Strawderman, and K.J. Pienta Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer J Clin Oncol 16 1998 1835 1843
23. P.F. Mulders, and J.A. Schalken Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer Prostate Cancer Prostatic Dis 12 2009 241 246
24. P.J. Saylor, U. Mahmood, A. Kunawudhi, M.R. Smith, E.L. Palmer, and M.D. Michaelson Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer J Nucl Med 53 2012 1670 1675
25. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
26. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
27. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
28. C. Parker, and O. Sartor Radium-223 in prostate cancer N Engl J Med 369 2013 1659 1660
29. R.J. Motzer, T.E. Hutson, and D. Cella Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 2013 722 731
30. I.F. Tannock, K. Fizazi, and S. Ivanov Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial Lancet Oncol 14 2013 760 768
31. K.N. Chi, S.L. Ellard, and S.J. Hotte A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer Ann Oncol 19 2008 746 751
32. S. Steinbild, K. Mross, and A. Frost A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV Br J Cancer 97 2007 1480 1485
33. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
34. K.L. Meadows, and H.I. Hurwitz Anti-VEGF therapies in the clinic Cold Spring Harb Perspect Med 2 2012
35. R.J. Lee, and M.R. Smith Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer Cancer J 19 2013 90 98
36. J. Dai, H. Zhang, and A. Karatsinides Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions Clin Cancer Res 2013
37. H.M. Nguyen, N. Ruppender, and X. Zhang Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling PLoS One 8 2013 e78881
38. R.J. Lee, P.J. Saylor, and M.D. Michaelson A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases Clin Cancer Res 19 2013 3088 3094
39. D.C. Smith, M.R. Smith, and C. Sweeney Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial J Clin Oncol 31 2013 412 419
40. American Association for Cancer Research. Stand Up To Cancer Dream Teams. Available at: http://www.aacr.org/home/public-media/stand-up-to-cancer/su2c-dream-teams.aspx. Accessed: March 2, 2014.